C4X Discovery Holdings plc
(“C4XD”, “C4X Discovery” or the “Company”)
2 August 2022 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today provides a business update on the continued progression across its Drug Discovery portfolio:
Dr Clive Dix, CEO of C4XD, said: “Our partnered portfolio has continued to deliver over the past few months, most notably with our first milestone payment from Sanofi for our oral IL-17a inhibitor to treat inflammatory diseases. This was an important further step in demonstrating the commercial value of C4XD’s expertise, approach to drug discovery, and its business model. Looking ahead, with partnering discussions advancing for our third programme, NRF2, we remain well positioned for growth as multiple partnerable assets in the pipeline continue strong progression.”
C4X Discovery Holdings plc
Mo Noonan, Communications+44 (0)7876 444 977
Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700
C4X Discovery (“C4XD”) is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.
We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.
This website uses 'cookies' to give you the best most relevant experience. To continue you have to agree to our use of cookies policy and how and why we use cookies.
You can change which cookies are set at any time and find out more about them by reading our privacy policy.